Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone Switch Study in Schizophrenia
NCT00159757Phase 4Terminated
- Sponsor
- Viatris
- Start
- Nov 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ziprasidone in schizophrenia, sponsored by Viatris. Primary endpoints: Positive and Negative Syndrome Scale Total Score at 12 weeks and Incidence and Severity of Side Effects at 12 weeks. Started Nov 2003; status: terminated.
02
Drugs
ziprasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00159757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159757.